WITHDRAWN:Knowledge and viewpoints on biosimilar monoclonal antibodies from members of the Asian Organization of Crohn’s and Colitis: comparison with European Crohn’s and Colitis members |
Soo-Kyung Park1, Tadakazu Hisamatsu2, Zhihua Ran3, Shu-Chen Wei4, Dong Il Park1 |
1Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea 2Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan 3Department of Gastroenterology, Shanghai Jiao Tong University, Shanghai, China 4Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
|
Correspondence:
Dong Il Park, Tel: +82-2-2001-2059, Fax: +82-2-2001-2049, Email: diksmc.park@samsung.com |
Received: 12 June 2018 • Revised: 5 September 2018 • Accepted: 6 October 2018 |
Key Words:
Biosimilar pharmaceuticals, Infliximab, Asia, Knowledge |
|